XEN-D0103: Phase II started

Xention began the double-blind, placebo-controlled, crossover, U.K. Phase II XAPAF trial to evaluate 50 mg oral XEN-D0103 twice daily for 28 days in 20 patients with paroxysmal AF who have implanted p...